Testosterone Plus Finasteride Improves BMD in Men With Low Testosterone.

Feb. 25, 2007 — The alliance propecia (T) and finasteride (F) improves bone mineral compactness (BMD) in men with low T levels without increasing prostate-specific antigen (PSA) levels, according to the results of a randomized visitation published in the February publication of the Axle of Clinical Endocrinology & Metamorphosis .
The editorialist warns that longer-term follow-up of PSA levels and of break risk is needed.
“Older men, particularly those with low serum T levels, might goodness from T therapy to improve BMD and reduce shift risk.
Concerns exist, however, about the impingement of T therapy on the prostate in older men,” write John K.
Amory, from the Establishment of George Washington Period of time of Penalization in Seattle, and colleagues. “We hypothesized that the social unit of T and F, a 5α-reductase inhibitor, might process BMD in older men without adverse effects on the prostate.”
In a three-way randomization, 70 men aged 65 life or older, with serum T less than 12.1 nmol/L on two occasions, received T enanthate, 200 mg intramuscularly every two weeks with vesper pills daily (T-only); T enanthate, 200 mg every two weeks with 5 mg F daily (T+F); or medicament injections and pills (placebo).
Low BMD was not a thing for entry.
Dual x-ray absorptiometry determined BMD of the lumbar thorn and hip at touchstone and serially.
Of the 70 men who entered the examination, 50 completed the 36-month code of conduct.
Intent-to-treat psychoanalysis including all men for as long as they provided data revealed that T therapy for 36 months increased BMD.
At the lumbar rachis, share change in BMD from measure was 10.2% ± 1.4% for T-only, 9.3% ± 1.4% for T+F, and 1.3% ± 1.4% for medicinal drug ( P < .001 for T groups vs. placebo).
At the hip, corresponding increases in BMD were 2.7% ± 0.7%, 2.2% ± 0.7%, and -0.2% ± 0.7%, respectively ( P
Compared with criterion, the bone-resorption artefact urinary deoxypyridinoline decreased significantly after six months of aid in both the T-only and T+F groups ( P < .001).
However, this writing implement was not significantly reduced in the T groups compared with the medicinal drug mathematical group.
During the 36-month written document, PSA levels increased from measure in the T-only radical ( P < .001).
Although prostate measure increased in all groups, this alteration was significantly less in the T+F abstract entity than in the T-only chemical group or in the medicament set ( P = .02).
The authors conclude that T therapy in older men with low serum T increases vertebral and hip BMD during 36 months of aid, either when given alone or in alignment with F, suggesting that dihydrotestosterone is not essential for the beneficial effects of T on BMD in men.
“In suburban area, the concomitant judicature of F with T appears to attenuate the impinging of T therapy on prostate size and PSA and might reduce the possibleness of benign prostatic hypertrophy or other prostate-related complications in older men on T therapy,” they write. “These findings have important implications for the prevention and direction of osteoporosis in older men with low T levels.”
The National Institutes of Well-being supported this drawing.
In an accompanying editorial, Elizabeth II Barrett-Connor, from the Educational institution of California at San Diego, and Shalender Bhasin, from the Educational institution of California in Los Angeles, refer to these results as “most impressive” but ask if they are clinically relevant.
They note that 30% of the men in the T radical required a dose reaction to manage a packed cell volume growth of 52% or greater, ascent concerns about the optimal dose.
This is a part of article Testosterone Plus Finasteride Improves BMD in Men With Low Testosterone. Taken from "Generic Propecia - Finasteride Archive" Information Blog